Japan Hotel REIT Investment (TSE:8985) just gave markets something to consider by releasing full-year earnings and dividend guidance for 2025, as well as a snapshot of operating results through July. The company expects steady numbers across revenue, net income, and dividends, which gives investors a clearer read on the REIT’s path into next year. With occupancy rates holding strong and revenue per available room showing resilience, it is no surprise that renewed investor interest is...
On August 26, 2025, Eli Lilly announced positive topline results from the Phase 3 ATTAIN-2 trial of orforglipron in adults with obesity or overweight and type 2 diabetes, meeting all primary and key secondary endpoints including significant weight loss, HbA1c reduction, and improvements in cardiometabolic risk factors.
This clinical milestone is significant for Chugai Pharmaceutical as a development partner for orforglipron, strengthening its pipeline and future product prospects through...